Now showing items 1-3 of 3

    • CES1 and SLC6A2 genetic variants as predictors of response to methylphenidate in autism spectrum disorders 

      Hernández Hernández, Marta; Bote, Valentin; Serra-Llovich, Alexandre; Cendros, Marc; Salazar, Juliana; Mestres Miralles, Concepción; Guijarro, Silvina; Alvarez, Aida; Lamborena, Cristina; Mendez, Iria; Sánchez, Bernardo; Hervas, Amaia; Arranz, Maria J (Pharmacogenomics and personalized medicine, 2022, vol. 15, p. 951-957, 2022-11)
      Purpose Autistic spectrum disorders (ASD) children and adolescents usually present comorbidities, with 40–70% of them affected by attention deficit hyperactivity disorders (ADHD). The first option of ...
    • Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders 

      Hervas, Amaia; Serra-Llovich, Alexandre; Rueda, Isabel; Targa, Irene; Guijarro, Silvina; Bigorra, Aitana; Cancino, Martha; Bote, Valentin; Cárcel, María; Amasi-Hartoonian, Nare; Hernández Hernández, Marta; Arranz, Maria J (Journal of Translational Genetics and Genomics, 2021, 5:278-287, 2021-07)
      Aim: About a third of patients with autism spectrum disorder (ASD) receive pharmacological treatment for comorbid symptoms. However, 30%-50% do not respond adequately and/or present severe and long-lasting ...
    • Pharmacogenetic interventions improve the clinical outcome of treatment-resistant autistic spectrum disorder sufferers 

      Arranz, Maria J; Salazar, Juliana; Bote, Valentin; Artigas-Baleri, Alícia; Serra-Llovich, Alexandre; Triviño, Emma; Roige, Jordi; Lombardia, Carlos; Cancino, Martha; Hernández Hernández, Marta; Cendros, Marc; Duran-Tauleria, Enric; Maraver, Natalia; Hervas, Amaia (Pharmaceutics, 2022, 14 (5), 999, 2022-05)
      BACKGROUND: Autistic spectrum disorders (ASD) are severe neurodevelopmental alterations characterised by deficits in social communication and repetitive and restricted behaviours. About a third of ...